Company profile
Summit Therapeutics Inc.
NASDAQ: SMMT · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
49DFH 47DQ 59GM 21SS 74
v0.1 · 65/100 weight · provisional
↑ Altman-Z, market scale · ↓ 3-yr revenue growth, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.1B
Employees
265
as of 2026-08-05
Market cap
$11.0B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02024
Net income-$1.1B-$1.1B2025
Operating income-$226.0M-$226.0M2024
Total assets$751.2M$751.2M2025
Liabilities$92.3M$92.3M2025
Equity$658.9M$658.9M2025
Revenue trend
FY2020 – FY2024 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
Revenue by segment
Filed disclosures · FY2022
By product
License and Service100%
By geography
Latin America100%
The read
What is Summit Therapeutics Inc.’s revenue?
Summit Therapeutics Inc. booked $0 in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
VMS Rehab Systems, Inc.——Goldenwell Biotech, Inc.16DRevolution Medicines, Inc.52DSpyre Therapeutics, Inc.64CPraxis Precision Medicines, Inc.61COruka Therapeutics, Inc.66BNeighbors
Middlesex →Key facts
CEORobert W. Duggan
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: SMMT
Employees265
IPO date2015-03-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.